Loading

PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support

PeerCurrent

PcPeerCurrent

Your Feed AI Summary Saved Board Expert Discussion This Week in Your Field

Follows Journals Trials Guidelines Markets

Set your cadence Alerts Settings Help

Back to follows

Researcher

Hideyuki Okano

Keio University Regenerative Medicine Research Center (KRM), Kanagawa, Japan.

1 development in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

For You Latest Breakthroughs Trials Reviews1 Guidelines1

Latest

Everything in the corpus, newest first.

JUN 15, 2026 · REVIEW/PERSPECTIVE

Therapeutic frontiers in ALS: iPSC-based drug discovery, cell therapy, and gene therapy-Advances through 2026.

Regenerative Therapy

Narrative review synthesizing therapeutic developments across multiple ALS modalities without original comparative efficacy data.

Expert GuidanceCell Therapy Shinichi Takahashi Hideyuki Okano

Reported

Proportion of sporadic ALS casesapproximately 90%

PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support